Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Atea Pharmaceuticals in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 1,920,000 shares, an increase of 8.5% from the August 31st total of 1,770,000 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average daily trading […]
JPMorgan Chase & Co Downgrades Atea Pharmaceuticals (NASDAQ:AVIR) to Underweight theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2023 earnings per share estimates for Atea Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 2,300,000 shares, a decrease of 12.9% from the August 31st total of 2,640,000 shares. Based on an average trading volume of 471,500 shares, the short-interest ratio is […]